Log in or Register for enhanced features | Forgotten Password?
White Papers | Suppliers | Events | Report Store | Companies | Dining Club

Inward Investment
Return to: PBR Home | Inward Investment | News
Search Refinements

Inward Investment News

View news from other Pharmaceutical sectors:
91-105 of 417 results
Merz acquires Cuvposa drug
By PBR Staff Writer
US affiliate of Merz Pharma, Merz has acquired Cuvposa (glycopyrrolate) oral solution, the only FDA approved treatment for pediatric chronic severe drooling (sialorrhea) associated with neurologic conditions such as cerebral palsy.
Inward Investment > News
Synergy takes over FV-100 shingles drug from Bristol-Myers
By PBR Staff Writer
Synergy Pharmaceuticals has signed an asset purchase agreement to acquire FV-100 shingles drug from Bristol-Myers Squibb Company.
Inward Investment > News
GSK to divest majority of Classic Brands in Australia
By PBR Staff Writer
GlaxoSmithKline (GSK) has announced an agreement with Aspen Global to divest majority of Classic Brands, including 25 non-promoted and genericised products in Australia for approximately £172m in cash.
Inward Investment > News
OPKO Health takes over Farmadiet
By PBR Staff Writer
OPKO Health, a biopharmaceutical and diagnostics company, has acquired Barcelona-based Farmadiet Group.
Inward Investment > News
GSK acquires Human Genome Sciences
By PBR Staff Writer
Research-based pharmaceutical and healthcare company GlaxoSmithKline (GSK) has completed acquisition of Human Genome Sciences (HGS) for $3.6bn on an equity basis, or approximately $3 billion net of cash and debt.
Inward Investment > News
CytoDyn to purchase Progenics PRO 140 anti-HIV drug
By PBR Staff Writer
CytoDyn has entered into an agreement to purchase Progenics Pharmaceuticals' proprietary humanized monoclonal antibody HIV viral-entry inhibitor drug candidate, PRO 140, for $3.5m.
Inward Investment > News
Boehringer purchases rights to Funxional's FX125L compound
By PBR Staff Writer
Boehringer Ingelheim and Funxional Therapeutics have signed an agreement under which Boehringer will acquire the global rights to Funxional's FX125L compound and somatotaxin program.
Inward Investment > News
Synergy, Callisto sign definitive merger agreement
By PBR Staff Writer
Callisto Pharmaceuticals will merge with Synergy Pharmaceuticals following a definitive merger agreement between both the companies.
Inward Investment > News
GlaxoSmithKline to takeover HGS
By PBR Staff Writer
GlaxoSmithKline (GSK) has signed a definitive agreement to acquire Human Genome Sciences (HGS) for $14.25 per share in cash.
Inward Investment > News
Amgen acquires KAI pharmaceuticals
By PBR Staff Writer
US based pharmaceutical company, Amgen has acquired KAI Pharmaceuticals.
Inward Investment > News
Genstar Capital takes over ERT
By PBR Staff Writer
Genstar Capital has completed the acquisition of the ERT in a take-private transaction valued at approximately $400m.
Inward Investment > News
Bristol-Myers Squibb to take over Amylin pharmaceuticals
By PBR Staff Writer
Bristol-Myers Squibb will acquire Amylin for $31.00 per share in cash, pursuant to a cash tender offer and second step merger, or a total buying price nearing $5.3bn.
Inward Investment > News
Cornerstone buys EKR Therapeutics
By PBR Staff Writer
Cornerstone Therapeutics has acquired a privately-held specialty pharmaceutical company focused on the acute-care hospital setting, EKR Therapeutics.
Inward Investment > News
InterMune completes sale of Actimmune
By PBR Staff Writer
InterMune has completed divestiture of Actimmune (interferon gamma-1b) to Vidara Therapeutics, a part of an international specialty pharmaceutical group of companies with operations in Ireland and the US.
Inward Investment > News
AstraZeneca takes over Ardea Biosciences
By PBR Staff Writer
AstraZeneca, a biopharmaceutical company, has completed the purchase of a US-based biotechnology company, Ardea Biosciences.
Inward Investment > News
91-105 of 417 results